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Abstract
Background: People with dementia progressively lose cognitive and functional abilities. Interventions promoting
exercise and activity may slow decline. We developed a novel intervention to promote activity and independence
and prevent falls in people with mild cognitive impairment (MCI) or early dementia. We successfully undertook a
feasibility randomised controlled trial (RCT) to refine the intervention and research delivery. We are now delivering a
multi-centred RCT to evaluate its clinical and cost-effectiveness.
Methods: We will recruit 368 people with MCI or early dementia (Montreal Cognitive Assessment score 13–25) and
a family member or carer from memory assessment clinics, other community health or social care venues or an
online register (the National Institute for Health Research Join Dementia Research). Participants will be randomised
to an individually tailored activity and exercise programme delivered using motivational theory to promote adherence
and continued engagement, with up to 50 supervised sessions over one year, or a brief falls prevention assessment
(control). The intervention will be delivered in participants’ homes by trained physiotherapists, occupational therapists
and therapy assistants. We will measure disabilities in activities of daily living, physical activity, balance, cognition,
mood, quality of life, falls, carer strain and healthcare and social care use. We will use a mixed methods approach to
conduct a process evaluation to assess staff training and delivery of the intervention, and to identify individual- and
context-level mechanisms affecting intervention engagement and activity maintenance. We will undertake a health
economic evaluation to determine if the intervention is cost-effective.
Discussion: We describe the protocol for a multi-centre RCT that will evaluate the clinical and cost-effectiveness of a
therapy programme designed to promote activity and independence amongst people living with dementia.
Trial registration: ISRCTN, ISRCTN15320670. Registered on 4 September 2018.
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Background
People living with dementia experience progressive and ir-
reversible loss of memory and other cognitive functions,
which is severe enough to affect daily functioning [1–3].
Loss of ability occurs due to multiple factors, including
cognitive impairment (memory loss, apraxia, executive
dysfunction), dementia-related motor and balance impair-
ment, physical co-morbidity, deconditioning and loss of
opportunity [2–4]. Restricted opportunity is often due to
concerns about safety, including risk of falling, and failure
to adapt activities to residual or individual abilities [5, 6].
Mild cognitive impairment (MCI) comprises cognitive im-
pairments that do not interfere with everyday activities,
but which progress to dementia at the rate of about 10%
per year [7, 8].
Moderate or vigorous intensity exercise, two to three
times a week, improves strength, gait speed and perform-
ance in activities of daily living (ADLs) [9–13] and may
slow cognitive decline [9, 12, 14–19]. Strength, balance
and dual-task training can improve executive function,
dual-task performance and gait parameters [20–25]. Func-
tionally oriented therapy can improve ability in ADLs [15,
26–28]. Progressive strength and balance training in older
people, with and without dementia, reduces risk of falling
and reduces carer strain and it can also potentially benefit
quality of life, mood and confidence [8–13, 29, 30].
FINALEX, a 12-month trial of an intensive, home-
based, supervised exercise programme for people with
dementia demonstrated a reduction in decline of ADLs
and halved the rate of falling [31]. This study showed
that, with the right support, people with dementia can
achieve and sustain an intensity of exercise needed to
gain health benefits. The challenge is how to achieve suf-
ficient participation, adherence and persistence in rou-
tine health and social care services. Additionally it is
necessary to establish how to translate individually tai-
lored home-based programmes for people with dementia
into sustainable programmes that are deliverable in the
community.
A clinical academic team comprising academic researchers,
occupational therapists, physiotherapists, rehabilitation sup-
port workers, health psychologists, nurses, geriatricians and
Patient and Public Involvement (PPI) collaborators devel-
oped a complex intervention aimed at promoting activity
and independence and reducing risk of falls for people living
with MCI or mild dementia (the PrAISED intervention) [32].
The core principles of the intervention include 150min of
physical activity per week (including balance-challenging
exercises), activities which are both active and functional,
encouraging positive risk taking, facilitating community or
environmental access and promoting independence [32].
The aim in intervening early is to enable people to ‘live well’
with dementia, prevent crises and establish positive health
habits before the inevitable progression of dementia.
The feasibility and practicability of delivering and evaluat-
ing the intervention has been established in a prior study
with 60 participants [33] (Goldberg et al., Promoting Activ-
ity, Independence and Stability in Early Dementia
(PrAISED): a feasbility, multisite, randomised controlled
trial, forthcoming). The feasibility randomised controlled
trial (RCT) enabled refinement of mechanisms for tailoring
the therapy programme to individuals’ needs and character-
istics. Research procedures were updated for the present
RCT to replace or omit measurement scales that did not
perform satisfactorily, and to ensure that an informant was
recruited for each participant. Additionally, we established
that blinded ascertainment of outcome data was impossible,
as inadvertent revelation of group allocation by participants
occurred in more than 80% of cases, despite considerable
efforts to maintain blinding [34].
Informed by results from the feasibility study, we now
present a protocol for a definitive, multi-centred RCT
(protocol version 2.3, 4th April 2019). The protocol has
been extensively peer reviewed as part of the funding ap-
plication process.
Aim
The aim of the study is to determine the clinical and
cost-effectiveness of a therapy programme to promote
activity and independence, as well as stability, amongst
people with early dementia and MCI.
Objectives and methods
The study objectives are to:
 Determine whether the intervention reduces
disability in ADLs; increases level of physical
activity; improves balance, quality of life, mood and
cognition; and decreases apathy, rate of falling, rate
of hospital and care home admission, days spent in
hospital and carer strain
 Determine if the intervention is cost-effective, within
the trial period, over the anticipated remaining life-
span of participants, using a social return on invest-
ment model
 Evaluate the individual- and contextual-level mecha-
nisms that contribute to study outcomes and evalu-
ate the implementation of the therapy programme.
Study design
A multi-centre, individually randomised, pragmatic,
parallel-group, controlled trial will be conducted (Fig. 1).
Participants will give informed consent, and will be ran-
domised to one of two arms: the intervention arm
comprising supervised therapy, or the control arm, com-
prising falls risk assessment and advice (Fig. 2). Mixed
methods will be used to undertake process evaluation
[35] and economic analyses. The Standard Protocol
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Items: Recommendations for Interventional Trials
(SPIRIT) checklist is provided as Additional file 1.
Setting
Recruitment will be from locality-based, secondary-care
memory clinics, general practice registers, dementia support
groups and the National Institute for Health Research
(NIHR) Join Dementia Research register. Intervention ses-
sions will be one-on-one with the participant and therapist,
delivered in the participant’s home or local community.
Recruitment
The trial will recruit 368 participants and family or carer
dyads from different sites in England. Recruitment will
be carried out by a study researcher, who will assess
mental capacity, take consent and collect baseline data
from both members of the dyad.
Participant inclusion/exclusion criteria
Participants will be eligible to participate if they meet the
following criteria: are age 65 years or older; have a diagno-
sis of MCI or dementia (of any subtype except dementia
with Lewy bodies); have a Montreal Cognitive Assessment
(MoCA) score of 13–25 (out of 30); have a family mem-
ber, informal carer or friend who knows the participant
well (defined as having contact with them for at least one
hour per week via Internet, telephone or in person) and
who is willing and able to act as an informant and be a re-
search participant. Participants with dementia/MCI must
be able to walk without human help, communicate in
English, be able to see and hear, have sufficient dexterity
to perform neuropsychological tests, have the mental cap-
acity to give consent to participate and consent to do so.
Participants will be ineligible to take part if they have a
diagnosis of dementia with Lewy bodies, a co-morbidity
preventing participation (e.g. severe breathlessness, pain,
psychosis, Parkinson’s disease or other severe neurological
disease) or they expect to be unavailable over the next year
(e.g. due to plans to relocate or go on a long holiday, or a
life expectancy of less than a year).
Participants will discontinue the intervention if they
withdraw consent or if the therapist overseeing their
care decides they are no longer able to take part (e.g.
due to illness or injury, progression of their disease
or inability to engage despite adjustment and tailoring
of the programme). Participants who withdraw will be
invited to remain in the trial for collection of out-
come measures if willing. Withdrawn participants
who have been randomised will not be replaced, as
the sample size calculations make allowance for drop-
out. Abrupt termination of study treatment will not
affect participant safety.
For the process evaluation [35], we aim to purposively
select a subsample of five participants and their carers at
Fig. 1 Schedule of enrolment, interventions and assessments
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each of the research sites. In addition, we will invite any
participants who withdraw from the study to be inter-
viewed, to explore their reasons for withdrawal.
Randomisation
Participants will be individually randomised, stratified by site,
the presence of a co-resident carer and history of previous
falls, using a dynamic, adaptive allocation algorithm [36]
accessed by a secure web portal to the system held at the
North Wales Organisation for Randomised Trials in Health
Clinical Trials Unit (NWORTH CTU), Bangor University.
The randomisation system will be maintained by a statisti-
cian independent of the analysis and research teams. Access
to the study website will be password protected. After
Fig. 2 Overview of participant-related study processes (recruitment, assessment, intervention and interviews)
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randomisation and irrespective of intervention group alloca-
tion, a member of the local research team will inform the
participant about the treatment and follow-up plan and in-
form the therapy provider so a visit can be arranged.
Blinding
Blinding of intervention is impossible for participants and
therapists administering the intervention. Blinding of re-
searchers to allocation during outcome assessment proved
impossible in practice during the feasibility study, as partici-
pants frequently inadvertently unblinded the researcher
(Goldberg et al., Promoting Activity, Independence and Sta-
bility in Early Dementia (PrAISED): a feasbility, multisite,
randomised controlled trial, forthcoming). This problem
has also been reported in similar trials [34]. Researchers
collecting baseline and outcome data will therefore not be
blinded to allocation. To minimise ascertainment bias, we
will use specific awareness training to avoid bias of re-
searchers and collection of hospital and resource use data.
We will use a ‘case manager’ system for recruitment and
data collection (having a single person undertake all assess-
ments and act as the main point of contact for a given par-
ticipant), which proposes to improve support to
participants, aiming to maximise retention in the study.
Statistical analysis will be blind to allocation.
Baseline data collection
Researchers will visit participants and their informants in
pairs, simultaneously interviewing the participants and in-
formant dyads individually to complete assessments. Assess-
ments will include (see Table 1):
1. Demographic and social variables
2. Medical and falls history, including previous fractures,
hospitalisation and drugs taken
3. Frailty and falls (SHARE frailty assessment and falls
diary) [50]
Table 1 Health status outcomes measured at baseline and after 12 months
Outcome Measured by Respondent
Activities of daily living DAD [37] Informant
NEADL [38] Patient
Quality of life EQ-5D-3L self [39] Patient
EQ-5D-5L proxy [39] Informant
DemQOL [40, 41] Patient
DemQOL proxy [40, 41] Informant
Depression, anxiety and apathy HADS [42] Patient
AES [43] Informant
Physical activity LAPAQ [44] Informant
Pedometer/accelerometer Patient
Balance and mobility Berg balance scale [45, 46] Patient
TUG [47] Patient
Dual-task TUG [47] Patient
Cognition CANTAB [48] Patient
MoCA [49] Patient
Verbal fluency (animal-naming task) Patient
Falls, fractures and frailty Diary Patient and informant
SHARE frailty assessment [50] Patient and informant
Admissions to and days spent in hospitals and care homes Diary Patient
Hospital records
NHS and social service costs CSRI [51] Informant
Carer strain CSI [52] Informant
Carer health-related quality of life EQ-5D-5L self [39] Informant
DAD Disability Assessment for Dementia, NEADL Nottingham Extended ADL scale, EQ-5D-3L EuroQoL five-dimension, three-level (self), EQ-5D-5L EuroQoL five-
dimension, five-level (proxy), DEMQOL and DEMQOL proxy Dementia Quality of Life, HADS Hospital Anxiety and Depression Scale, AES Apathy Evaluation scale,
LAPAQ Longitudinal Ageing Study Amsterdam Physical Activity Questionnaire, Pedometer Misfit Shine 2, TUG Timed Up and Go, CANTAB Cambridge
Neuropsychological Test Automated Battery, MoCA Montreal Cognitive Assessment, CSRI Client Service Receipt Inventory, CSI Caregiver Strain Index, NHS National
Health Service
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4. Blood pressure, sitting and standing (Omron M6
comfort (HEM-7321-E) automatic
sphygmomanometer)
5. Cognition (MoCA, animal-naming verbal fluency
task and Cambridge Neuropsychological Test Auto-
mated Battery) [48, 49]
6. Mood (Hospital Anxiety and Depression Scale and
Apathy Evaluation Scale) [42, 43]
7. Activities of daily living (Nottingham Extended
Activities of Daily Living questionnaire and
Disability Assessment for Dementia [DAD]) [37, 38]
8. Physical activity (Longitudinal Study of Ageing
Amsterdam physical activity questionnaire and
Misfit Shine accelerometer) [44]
9. Quality of life (Dementia Quality of Life
[DEMQOL], EuroQoL five-dimension three level
[EQ-5D-3L] and EQ-5D-5L) [39–41]
10. Balance and mobility (Berg balance scale, Timed Up
and Go, dual-task Timed Up and Go) [45–47]
11. Health and social care resource use (Client Service
Receipt Inventory [CSRI]) [51]
12. Carer strain (Caregiver Strain Index), carer health-
related quality of life (EQ 5D-5L), participant ser-
vice use (CSRI) [51, 52]
13. Personality (Big Five Inventory-10) [53].
Intervention
The trial will compare the active and control interven-
tions. The development and content of the programme
has been published [32].
Active intervention
The intervention programme will be tailored to individual
abilities, co-morbidities, interests and goals. The interven-
tion includes progressive strength and balance exercises;
functional activities and risk analysis, training and advice;
and environmental assessment and dual-task training, de-
livered using a motivational approach [32]. We will use a
specially developed stratification tool to determine the fre-
quency of intervention sessions for each participant to en-
able them to sustain the programme. Participants will
receive between 9 and 50 visits from the trained study
therapists and rehabilitation support workers over 52
weeks to directly supervise exercise, assess progress and
provide progressively challenging activities and exercises.
The programme is tapered to encourage habit formation
and the continuation of self-directed exercise and activity
between supervised sessions and after the programme has
been completed. An option to pause or suspend the
programme will be allowed to account for individual cir-
cumstances (such as holidays, illness or bereavement).
Participants will be encouraged to perform their inter-
vention programme for at least 3 h per week. Previous
guidance suggests at least 150 min of physical activity to
promote healthy ageing [54] and at least 180min of
balance-challenging and progressive strengthening exer-
cise per week to prevent falls [55]. A similar intensity has
also been shown to improve neuropsychological function
[25]. Spouses, partners, family members or carers are en-
couraged to support or participate as each individual cir-
cumstance allows. To encourage persistence after the
intervention sessions and regular supervision ceases, par-
ticipants will be introduced to local exercise, activity and
community classes.
Control
The control intervention has been modelled on usual care,
consisting of a fall prevention assessment and follow-up.
Control participants will receive an initial therapy visit and
assessment within 2 weeks of the research assessment (base-
line). This visit will be 90min in duration. A further two
visits are permitted (each of 90min) by either the assessing
therapist or rehabilitation support worker in order to review
actions or expand on any advice provided following the falls
assessment (for example, to seek a medicine review with the
participant’s general practice physician). The advice and rec-
ommended actions are prompted by the falls assessment
[56] and include actions for the participant (e.g. wearing
more suitable footwear), the therapists (e.g. referral to local
services) or both. Each visit received by the control partici-
pant will be 90min in duration and will be completed within
3months. The control participants are seen by the same
group of therapists who administer the intervention.
Concurrent treatment
All other interventions will be permitted, in both study
arms, including cognitive stimulation therapy, use of
acetylcholine inhibitor or memantine drugs or referral to
mental health, medical, rehabilitation or falls prevention
services. There are no arrangements for ancillary or post-
trial care beyond routine clinical care. There are no special
arrangements for compensation for non-negligent harm
resulting from trial participation.
Follow-up and outcomes
Each participant will take part for 15months. After 6
months, informants will be asked to complete the EQ-5D-
5L proxy [39], DEMQOL-U items from the DEMQOL
measure [41] and the Short CSRI [51] about the participant,
via post, with telephone calls to prompt or support as
needed. The main follow-up is after 12months (+/− 4
weeks), when two researchers will visit the dyads at home
to collect outcome data by interviewing the participant and
informant separately (Table 1). In the feasibility study, the
follow-up rate at 12months was 80% without differential
loss between arms (Goldberg et al., Promoting Activity, In-
dependence and Stability in Early Dementia (PrAISED): a
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feasbility, multisite, randomised controlled trial,
forthcoming).
Participants will keep a monthly diary for falls and ser-
vice use between months 0 and 15, with telephone calls
to prompt or support as needed. Therapists delivering
the intervention sessions will not be permitted to use
or prompt the use of the monthly diary for either
study arm.
For falls, the incidence rate ratio will be compared for
the intervention and control groups. For all other out-
come measures, the standardised effect size estimate (d)
of the difference between the groups’ follow-up scores
will be based on analysis of covariance (ANCOVA),
which will take into account the baseline scores on the
measures. Data will be aggregated using mean score un-
less descriptive statistics show the data to be substan-
tially skewed or non-normal.
Falls, programme adherence and service use
Adherence to the PrAISED programme, occurrence of
falls and health and social care service use will be collected
by monthly self-completed diaries. The nominated carer
will be asked to prompt and oversee this task. Telephone
calls will be made to prompt or support as needed.
Process evaluation and motivation study
The process evaluation of the trial will follow Medical
Research Council guidelines for the process evaluation
of complex interventions [57]. It will be used to gather
data around the implementation of the intervention, the
mechanisms of impact and contextual factors and partic-
ipants’ motivations [35].
The process evaluation will answer the question ’How
does the intervention work?’ by identifying the mediating
factors that contribute to study outcomes. It will use a
mixed methods design and will comprise two studies.
The implementation study will examine the training pro-
vided to therapists and how the intervention is delivered
to participants, by looking at four domains:
 Fidelity (the consistency of training and delivery of
the intervention)
 Adaptations (alterations made to training and
delivery, to achieve better contextual fit)
 Dose (how much training and intervention is
delivered)
 Reach (the extent to which therapists and
participants come into contact with the
intervention).
The study on the mechanisms of impact and context
will focus on the individual- and context-level mecha-
nisms that contribute to study outcomes. These will be
investigated through semi-structured interviews with
participants and carers from each site. To ensure that
the full range of perspective is gathered, we will purpos-
ively recruit participants with dementia/MCI from four
different groups:
 Low adherers to the PrAISED programme (i.e.
participants who have undertaken less than 150 min
of physical activity per week on average before the
first set of interviews at month 6, as recorded on the
calendar)
 High adherers to the PrAISED programme
(i.e. participants who have undertaken more than
150 min of physical activity per week on average
before the first set of interviews at month 6, as
recorded on the calendar)
 Those who self-withdraw
 Participants from the control group.
Clinicians will also be interviewed about their experi-
ences of receiving training and delivering the interven-
tion. Details of the process evaluation can be found in
the published protocol [35].
Data from the qualitative interviews of the process
evaluation will be used to investigate motivational fac-
tors linked to adherence.
Economic evaluation
We will determine if the intervention is cost-effective, by
comparing utilities derived from EQ-5D and DEMQOL-
U, with costs. Costs will be separately determined from
health service, public-sector multi-agency and private or
informal care perspectives. We will consider time frames
of the trial period, and the anticipated remaining lifespan
of participants, using Markov modelling. We will also
use a social return on investment model [58]. These ana-
lyses will be subject to a separate protocol.
Adverse events
Adverse event (AE) monitoring will begin when a par-
ticipant has been randomised and will continue for 15
months. We will record AEs which are defined as ser-
ious (involving death, life-threatening events, hospitalisa-
tion, significant disability or incapacity) or which are
potentially related to the intervention or to exercise
undertaken independently. Inter-current illness, progres-
sion of dementia, loss of function, hospitalisation and
death are likely to be common in this population given
their age and frailty. We will assess all reported AEs for
severity and relatedness to the intervention.
The intervention group will have more contact with
professional staff than the control group, and therefore
greater opportunity to report AEs, presenting a potential
bias. We will screen falls diaries and medical records to
ascertain core AEs across both arms. For purposes of
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comparing the safety of the intervention, we will con-
sider ’deaths’, ’hospital admissions’ and ’falls’ to be core
AEs. These will be ascertained and analysed as part of
the core research dataset, independently of incidental
reporting, and should therefore be more robust to infor-
mation bias.
Data management
A data management plan will be drawn up by NWORTH
CTU as part of the trial setup. Data will be entered locally
using the MACRO data entry system. For each time point
and for each site, 5% of the cases entered into MACRO
will be checked against the data recorded on the paper
case report forms. All study co-applicants and researchers
will have access to the final trial dataset. There are no con-
tractual agreements limiting access for investigators.
Statistics and data analysis
A Statistical Analysis Plan will be agreed between a CTU
trial statistician, a second statistical advisor (based at the
CTU) and the Chief Investigator, before completion of
data collection. The Data Monitoring and Ethics Com-
mittee (DMEC) and the Programme Steering Committee
(PSC) will approve the Statistical Analysis Plan.
Analyses will be undertaken by the CTU and will be
performed blind to group allocation.
The first 50 randomised participants will constitute the
sample for an internal pilot, to check on recruitment and
data completion. There will be no other interim analyses.
Sample size and justification
The primary outcome is the Disability Assessment for
Dementia (DAD) at 12 months [37]. A sample size of
184 participants per group, including 23% attrition
(based on previous studies [10, 31]), has 80% power to
detect changes in the disability outcome, DAD, with ef-
fect size 0.5 (11 points on a baseline of 70, standard de-
viation 22, data from [10, 13]). This sample size has
been rechecked using data from the feasibility study and
confirmed to be a conservative estimate.
Baseline comparison
Baseline variables will be compared across groups using
means, medians or proportions as appropriate.
Assessment of efficacy
Analyses will be conducted on an intention-to-treat basis.
Missing data for outcome measures will be imputed, using
multiple imputation, if more than 5% of the data are miss-
ing and data are shown to be missing at random.
We will compare the DAD scores between the inter-
vention and the control groups, adjusting for stratifying
variables and any baseline imbalances in an ANCOVA
model. Adjusted mean differences between groups and
standardised effect size estimates (equivalent to Cohen’s
d [59]) will be calculated.
Rate of falls will be compared between the intervention
and the control groups using the incidence rate ratio, from
a negative binomial regression model, adjusted for baseline
imbalance or variables with prognostic importance [60, 61].
Other secondary outcomes will be compared between
the intervention and the control groups using ANCOVA
to adjust for baseline imbalance or variables with prog-
nostic importance.
Dissemination
Results will be disseminated via a peer-reviewed report
to the funder, which will be freely available, and through
open access journal articles and conference presenta-
tions. We will inform participants of the results through
a newsletter. Standard journal authorship criteria will
apply; there will be no use of professional writers. Public
or professional access to the full protocol, participant-
level data and statistical code, for bona fide academic
purposes, will be by request to the Chief Investigator.
Patient and Public Involvement (PPI)
The study team includes two patient and public collabora-
tors who have been involved in the development of the
intervention, trial and additional evaluations. The PPI con-
tributors worked with the study team to design participant
facing materials (see Additional files 2, 3 and 4 for study
consent form and participant information sheets) and
contributed to the study design and management. The
PPI contributors are co-researchers for the process evalu-
ation, motivation and adherence study and will work with
the research team to develop the interview topic guides,
interview participants, analyse data and disseminate find-
ings (e.g. attending conferences, delivering lectures and
seminars and co-authoring papers for publication). Two
external PPI representatives sit on the PSC.
Governance
An independent PSC and DMEC will meet six-monthly
in accordance with NIHR procedures. The trial sponsor
is Research and Innovation, Nottingham University Hos-
pitals National Health Service (NHS) Trust, NG7 2UH.
Any decision to terminate the trial will be taken on the
advice of the PSC, in conjunction with the sponsor and
funder. Site visits will be undertaken every 6 months by
co-ordinating centre researchers to audit compliance
with trial procedures. Protocol changes will be commu-
nicated to sites within 35 calendar days in accordance
with NIHR Clinical Research Network procedures.
Discussion
We developed a complex intervention, and successfully
conducted a feasibility RCT to demonstrate the
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practicability of its delivery, and of undertaking research
procedures in this population and setting [32, 33]. We
now present the protocol for a multi-centre RCT to de-
termine its clinical and cost-effectiveness.
Dementia is progressive, affecting memory, other
cognitive abilities and motor performance [4–6, 62].
These impairments impact an individual’s abilities to
perform day-to-day activities and are linked to an in-
creased risk of falls [4, 6]. Falls and related injuries
lead to immobility, inactivity, loss of independence
and increased dependence [62]. Early interventions
aimed at maintaining activity and independence,
which are specifically designed for individuals with de-
mentia, may enable people to live well, prevent crises
and reduce dependency. Exercise, strength, balance
and dual-task training may have positive benefits, in-
cluding improvements in gait speed and performance
of activities of daily living, slowed cognitive decline
and improved mood and confidence, whilst reducing
the risk of falls [9–14, 29, 30].
People with MCI and mild dementia retain functional
ability and independence, but are at high risk of progres-
sion and deteriorating health status. The range of neuro-
psychological deficits in MCI is similar to that in
dementia [4, 63], and the distinction between the two is
arbitrary (depending on the difficulty of daily activities
considered). This provides the justification for consider-
ing the two conditions together. Pharmacological inter-
ventions are of limited efficacy in improving outcomes
or slowing progression in these conditions [64]. New
learning and adaptation are possible, but many interven-
tions in dementia have proven ineffective when subject
to rigorous evaluation. However, there are precedents
for demonstrating effectiveness [24, 25, 27, 65]. The
intervention that we describe is complex, reflecting the
need to address multi-faceted problems, individual vari-
ation and real-world clinical practice. Our evaluation
uses mixed research methods, to demonstrate clinical
and cost-effectiveness, but also to understand how the
intervention operates, what influences motivation and
engagement and the necessary conditions for success
and for potential future implementation.
Research involving people with cognitive impairment
can be difficult, requiring adaptation and attention to their
particular needs. Participants are potentially vulnerable,
and thus careful, ongoing attention to the assessment of
mental capacity and consent to participate is required.
Progressive memory impairment challenges assessment of
aspects of health status and ascertainment of healthcare
and social care resource use, requiring the involvement of
an informant. Experience of both ill health and healthcare
includes multiple stakeholders, especially family carers,
whose perspective must be included, requiring them to be
included as research participants.
Recording of activity and falls through self-completion
of diaries can be challenging, but we demonstrated in
the feasibility trial that involving a family member and
providing regular postal reminders can be effective
mechanisms to aid participants to record such informa-
tion (Goldberg SE, et al., ‘Promoting Activity, Independ-
ence and Stability in Early Dementia (PrAISED): a
feasibility, multisite randomised controlled trial’; in prep-
aration). High-level outcomes, such as quality of life,
have multiple influences, including co-morbidities and
socio-economic factors, which may not be amenable to
therapeutic intervention. Complex interventions require
measurement of a battery of outcomes, both to describe
the impact of an intervention and to understand its
mechanism, at the risk of type I statistical error through
multiple comparisons. We paid particular attention to
measures to achieve engagement and sustained adher-
ence to the intervention over a long period of time,
which appeared to be successful in the feasibility study.
In the feasibility RCT we found that outcome assessor
blinding was not possible (Goldberg SE, et al.; in prepar-
ation). Previous studies have reported similar challenges
to outcome assessor blinding in trials of home-based ex-
ercise interventions for older people [34]. We decided
that outcome assessors will not be blinded to interven-
tion in this trial, but to mitigate the potential bias this
may introduce, all researchers conducting outcome as-
sessments will complete specific anti-bias training.
This RCT is part of a research programme aimed at
understanding activity limitation amongst people with
dementia, how to intervene to promote activity and pro-
long independence and also how to get such a therapy
programme to work in practice. The RCT opened to re-
cruitment in October 2018 and will close recruitment in
March 2020.
Trial status
The trial opened to recruitment in October 2018 and
will close to recruitment in March 2020 (protocol ver-
sion 2.3 4th April 2019).
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3871-9.
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in a clinical trial protocol and related documents.
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Additional file 4. Summary participant information sheet.
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